Paolo Tarantino: Long term outcomes from KATHERINE are out
Paolo Tarantino, Clinical Research Fellow at the Dana-Farber Cancer Institute, shared a recent article by Charles E. Geyer et al. on X:
“Long-term outcomes from KATHERINE out in The New England Journal of Medicine.
Post-neoadjuvant escalation of therapy with a HER2 ADC (T-DM1) in patients with HER-positive breast cancer and residual disease meaningfully improves 7-year iDFS (Δ 13.7%) and OS (Δ 4.7%).
Congrats to the authors.”
“Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer“
Authors: Charles E. Geyer, Michael Untch, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo, Hans H. Fischer, Véronique D’Hondt, Alison K. Conlin, Valentina Guarneri, Irene L. Wapnir, Christian Jackisch, Claudia Arce-Salinas, Peter A. Fasching, Michael P. DiGiovanna, John P. Crown, Pia Wuelfing, Zhimin Shao, Elena Rota Caremoli, Hervé R. Bonnefoi, Bryan T. Hennessy, Ljiljana Stamatovic, Hugo Castro-Salguero, Adam M. Brufsky, Adam Knott, Asna Siddiqui, Chiara Lambertini, Thomas Boulet, Beatrice Nyawira, Eleonora Restuccia and Sibylle Loibl
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
More posts featuring Paolo Tarantino.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023